z-logo
open-access-imgOpen Access
Cryopreserved amniotic membrane and umbilical cord particulate matrix for partial rotator cuff tears
Author(s) -
J. Freeland Ackley,
Michael Kolosky,
Danielle Gurin,
Robert Hampton,
Richard Masin,
David Krahe
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016569
Subject(s) - medicine , rotator cuff , tears , range of motion , magnetic resonance imaging , surgery , umbilical cord , refractory (planetary science) , adverse effect , orthopedic surgery , radiology , physics , anatomy , astrobiology
Amniotic membrane (AM) and umbilical cord (UC) are well known to have anti-inflammatory properties and have been shown to promote healing in various orthopedic indications. This study investigated whether intra-articular injection of AM/UC particulate matrix promotes healing of partial rotator cuff tears (RCTs). A case series was performed on 10 patients that received injection of 50 mg AM/UC for partial RCTs that were refractory to conservative treatment. Outcomes included Penn Shoulder Score (PSS) questionnaire, range of motion examination, and magnetic resonance imaging (MRI) analysis before and at 6 months. Final MRI analysis was performed by a musculoskeletal radiologist in a blinded fashion. Average PSS score (out of 100) increased from 46.8 ± 23.7 at baseline to 82.0 ± 19.1 at 6 months. The average PSS sub-scores of pain, satisfaction, and function increased 78.4%, 37.1%, and 82.3% from baseline, respectively. The subject's range of motion was 77.9% at baseline and increased to 99.9% at 6-months. Follow-up MRI scans did not demonstrate any significant change in RCT size. No adverse events were noted. This small case series provides preliminary data for use of cryopreserved AM/UC particulate matrix in patients with refractory partial RCTs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here